Apitope Announces Management Changes

Keith Martin to retire as CEO, continue as Non-Executive Director
Hayley French appointed COO and interim CEO

HASSELT, Belgium, and CHEPSTOW, UK, 24 October 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that Chief Executive Officer (CEO) Dr Keith Martin has decided to retire from the CEO role after 12 years at the helm of Apitope. He will remain on the Apitope Board as a non-executive director. Dr Hayley French will move to Chief Operations Officer (COO) and act as interim CEO of Apitope until a permanent replacement is in place. Dr French will join the Board of Directors effective immediately.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH